EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Coden USA: EJBPBO
Volume: 13
Issue: 2
Year: 2026

ADVANCES IN STABILITY-INDICATING RP-HPLC METHODS FOR FIXED-DOSE ANTI-MALARIAL COMBINATIONS: A COMPREHENSIVE REVIEW

Sarvepalli Gnana Samanvitha[1], Shweta Purohit Nayak[1*], Shaik Naziya Fathima[1], MD. Saniya[1], Mallani Sirisha[1], Arunabha Mallik[2]

[*1]Department of Pharmaceutical Chemistry, Marri Laxman Reddy Institute of Pharmacy, Dundigal, Hyderabad, Telangana – 500046, India.
[2]Department of Pharmacology, Marri Laxman Reddy Institute of Pharmacy, Dundigal, Hyderabad, Telangana – 500046, India.

***Corresponding Author: Shweta Purohit Nayak**
Department of Pharmaceutical Chemistry, Marri Laxman Reddy Institute of Pharmacy, Dundigal, Hyderabad, Telangana – 500046, India. **DOI:** https://doi.org/10.5281/zenodo.18438329

How to cite this Article: Sarvepalli Gnana Samanvitha[1], Shweta Purohit Nayak[1*], Shaik Naziya Fathima[1], MD. Saniya[1], Mallani Sirisha[1], Arunabha Mallik. (2026). Advances In Stability-Indicating Rp-Hplc Methods For Fixed-Dose Anti-Malarial Combinations: A Comprehensive Review. European Journal of Biomedical and Pharmaceutical Sciences, 13(2), 01–05.

Article Received on 05/01/2026 **Article Revised on 25/01/2026** **Article Published on 01/02/2026**

ABSTRACT
Fixed-dose combinations (FDCs) of anti-malarial drugs play a crucial role in global malaria control by improving therapeutic efficacy, enhancing patient compliance, and minimizing resistance development. As these products often contain chemically diverse actives such as artemisinin derivatives, Lumefantrine, Amodiaquine, Mefloquine, Piperaquine, and Sulfadoxine-Pyrimethamine robust stability-indicating analytical methods are essential to ensure safety, efficacy, and regulatory compliance. Reversed-phase high-performance liquid chromatography (RP-HPLC) remains the most widely adopted analytical platform for stability studies due to its high resolution, reproducibility, selectivity, and compatibility with a broad range of pharmaceutical matrices. This comprehensive review summarizes the recent advances in stability-indicating RP-HPLC method development for anti-malarial FDCs, focusing on chromatographic conditions, forced degradation studies, validation parameters, green analytical initiatives, and Quality by Design (QbD) strategies. Current trends emphasize eco-friendly solvents, miniaturized sample preparation, novel stationary phases, and regulatory alignment with ICH Q1A (R2) and Q2 (R2). Critical challenges and future prospects for analytical improvement in anti-malarial quality control are highlighted.

KEYWORDS: Stability-indicating RP-HPLC, Anti-Malarial Fixed-Dose Combinations, Artemether and Lumefantrine, Artesunate and Amodiaquine.

1. INTRODUCTION
Malaria remains a major public health challenge in tropical and subtropical regions, with more than 240 million cases reported annually. Fixed-dose anti-malarial combinations (FDCs) serve as the backbone of malaria treatment because they improve synergistic action, reduce the risk of drug resistance, and offer simplified dosing regimens.[1] Examples include

* Artemether–Lumefantrine
* Artesunate–Amodiaquine
* Artesunate–Mefloquine
* Dihydroartemisinin–Piperaquine
* Sulfadoxine–Pyrimethamine

Due to the inherent instability of artemisinin derivatives and the chemical diversity of combination therapy components, stability-indicating methods are essential to assess degradation, ensure product integrity, and comply with regulatory expectations.[2]

RP-HPLC is widely preferred due to its suitability for non-volatile, thermolabile compounds, high resolution for multi-component systems, and flexibility in optimizing chromatographic conditions. Over the past decade, advances in column technologies, mobile phase systems, and forced degradation protocols have significantly improved analytical performance for anti-malarial FDCs.[3]

This review provides an in-depth analysis of the progress in stability-indicating RP-HPLC methods, highlighting evolving analytical trends, regulatory requirements, and opportunities for future innovations.

2. Literature Review

2.1 Importance of Stability-Indicating Methods

A stability-indicating method (SIM) accurately quantifies the analyte while resolving degradation products formed during stress conditions. Regulatory guidelines such as ICH Q1A (R2) and Q2 (R2) mandate forced degradation studies involving hydrolytic, oxidative, photolytic, and thermal stress.[4,6]

Anti-malarial FDCs present unique challenges due to
* Chemical incompatibility among components
* Light-sensitive artemisinin derivatives
* Base/acid labile structures in partner drugs
* Complex formulation matrices
* High proportion of hydrophobic components

2.2 Types of Anti-Malarial FDCs Analyzed via RP-HPLC

Common combinations evaluated for stability include.[7]

Table-1: Types of Anti-Malarial FDCs.

Combination	Typical Challenges	Notes
Artemether & Lumefantrine	Low Solubility, Oxidative Degradation	Widely used first-line therapy
Artesunate and Amodiaquine	Artesunate instability in aqueous solutions	Requires rapid sample handling
Dihydroartemisinin and Piperaquine	Photolability of DHA	Piperaquine highly basic
Sulfadoxine and Pyrimethamine	Stable combination	Long retention due to lipophilicity
Artesunate and Mefloquine	Hydrolysis of Artesunate	Used in Southeast Asia

2.3 Chromatographic Trends in Recent Studies

A. Mobile Phase Composition

Acetonitrile–buffer mixtures remain dominant due to better peak shape for hydrophobic drugs.
* Methanol used as greener alternative.
* pH range 3.0–4.5 commonly applied for optimal drug ionization.[8]

B. Columns Used

* C18 columns remain standard due to compatibility with lipophilic Anti-Malarials.
* Emerging columns:
- Core-shell silica (higher efficiency)
- Polar-embedded C18 (improved peak shape for basic analytes)
- Phenyl-hexyl (π–π interactions for artemisinin derivatives)

C. Detection Wavelengths

* Typical λmax values:
- ✓ Artemether: 210–225 nm
- ✓ Lumefantrine: 335–340 nm
- ✓ Amodiaquine: 285 nm
- ✓ Piperaquine: 254–265 nm

* PDA detectors preferred for peak purity evaluation[9].

D. Forced Degradation Findings

Most degradation occurs under:
* Acidic hydrolysis (e.g., Artesunate → dihydroartemisinin)
* Oxidative conditions (Lumefantrine Oxidation)
* Photodegradation (Artemether, DHA)

3. Method Development in Stability-Indicating RP-HPLC

3.1 Stepwise Method Development Strategy

A. Selection of Chromatographic Mode

* RP-HPLC chosen due to suitability for lipophilic analytes.

B. Solubility Studies

* Anti-Malarials often require DMSO, methanol, or acetate buffers for better solubility.[10]

C. Mobile Phase Optimization

* Organic phase: ACN or MeOH
* Aqueous phase: phosphate buffer or formic acid (0.1–0.5%)
* Avoid high pH (>6) to prevent silica degradation.

D. Gradient vs. Isocratic Methods

* FDCs require gradient elution to separate components with varying logP values.

E. Column Selection

* 250 × 4.6 mm, 5 µm C18 widely used
* Core-shell columns reduce run time by 30–40%.

F. Flow Rate and Temperature

* 1.0 mL/min, 30–40°C optimal for peak shape.

3.2 Forced Degradation Studies[11]

Conducted under:

Table-2: Conditions of Forced Degradation Studies.

Stress Condition	Drug Effects Observed
Acid hydrolysis	Artesunate → DHA; Amodiaquine cleavage
Base hydrolysis	Piperaquine degradation
Oxidation (H_2O_2)	Lumefantrine oxidation products

Photolysis	Strong Degradation of Artemisinin Derivatives
Thermal	Mild Decomposition

Chromatograms must demonstrate baseline separation of degradants.

4. Method Validation
Validation follows ICH Q2 (R1/R2) guidelines.[12,16]

4.1 Specificity
Confirmed using PDA-based peak purity.

4.2 Linearity
Typical ranges:
* Artemether: 5–50 µg/mL
* Lumefantrine: 10–120 µg/mL
* Piperaquine: 5–100 µg/mL
Correlation coefficient (R^2) usually > 0.999.

4.3 Accuracy
Recoveries in the range of 98–102%.
4.4 Precision
%RSD < 2% for:
* Repeatability
* Intermediate precision.[17]

4.5 LOD and LOQ
Achieved using:
* LOD: 0.1–0.5 µg/mL
* LOQ: 0.3–1.5 µg/mL

4.6 Robustness
Common parameters tested
* Flow ±0.1 mL/min
* Temperature ±5°C
* pH ±0.2 units

4.7 System Suitability[18,20]
* Theoretical plates (N): > 3000
* Tailing factor < 2
* Resolution > 2 between components and degradants.

5. DISCUSSION
Stability-indicating RP-HPLC methods have significantly evolved for anti-malarial FDCs. Key trends include

5.1 Improved Separation Efficiency
- Core-shell and polar-embedded column technologies enhance separation of structurally diverse anti-malarial drugs.[21]
- Gradient elution strategies reduce retention time for hydrophobic drugs like Lumefantrine.

5.2 Enhanced Degradation Profiling
Modern PDA and MS detectors provide deeper insights into:
- ✓ Oxidative degradation pathways
- ✓ Photolytic instability of artemisinin derivatives

5.3 Move Toward Green Analytical Chemistry
Innovations include:
- Reduced organic solvent consumption
- Methanol replacing ACN
- Miniaturized sample preparation.[22]
- Shorter run times (<10 min)

5.4 QbD-driven Analytical Method Development
QbD has strengthened method robustness through
* DoE-based optimization of mobile phase ratio
* Risk assessment tools (FMEA, Ishikawa)
* Design space establishment

5.5 Challenges in Anti-Malarial FDC Analysis
* Differences in solubility and polarity
* Rapid degradation of artemisinin derivatives
* Multicomponent matrices requiring advanced gradient methods.[23-24]

6. Future Scope and Challenges
6.1 Future Scope
1. Integration of Advanced Detection Techniques
Future HPLC methods for anti-malarial fixed-dose combinations (FDCs) are expected to incorporate advanced hyphenated techniques such as LC–MS/MS, UHPLC–MS, and QTOF-MS. These systems will enable:
* More sensitive detection of low-dose components
* Better identification of unknown degradation products
* Faster chromatographic runs with improved resolution

2. Green Analytical Chemistry (GAC) Approaches
There is increasing scope for developing environmentally sustainable, stability-indicating RP-HPLC methods using:
* Reduced organic solvent consumption
* Ethanol or propylene carbonate as greener alternatives
* Shorter run times and smaller column dimensions
* Aqueous-based or micellar liquid chromatographic systems
Implementing GAC principles will align future analytical methodologies with global environmental frameworks.

3. Quality by Design (QbD)-Driven Method Development
QbD strategies will become routine for anti-malarial FDC analysis. Future research will focus on:
- ✓ Design of Experiments (DoE) for chromatographic optimization
- ✓ Establishing method operable design regions (MODRs)
- ✓ Creating robust, regulatory-compliant analytical control strategies

This will reduce method variability and improve reproducibility across laboratories.

4. Stability Profiling Under Emerging Stress Conditions

Future studies should address:

* Photodegradation under LED/UV-A light sources
* In-depth humidity-induced degradation pathways
* Drug–excipient interaction modeling using chemometrics
* Real-time and accelerated stability simulations

Such efforts will strengthen the understanding of degradation kinetics in tropical climates where malaria is endemic.

5. Analytical Techniques for Novel Anti-Malarial FDCs

With the development of new ACT formulations such as:

* *Artefenomel + Piperaquine
* Tafenoquine-based combinations
* Triple ACTs (TACTs)

Future methods must be adaptable, sensitive, and capable of resolving structurally similar components.

7. Challenges

i. Complexity of Artemisinin Derivatives

Artemisinin-based drugs are highly unstable and prone to degradation under:

* Heat
* Light
* Oxidative conditions

Their weak chromophores also reduce UV detection sensitivity, posing challenges for accurate quantification.

ii. Co-elution in Fixed-Dose Combinations

Many FDCs contain components with:

* Similar polarity
* Overlapping UV spectra
* Large differences in dose strength

Achieving adequate chromatographic resolution without excessively long run times remains a major challenge.

iii. Limited Availability of Degradation Standards

Identifying and quantifying degradation impurities are difficult because:

* Reference standards are expensive or unavailable
* Degradation pathways are complex and multi-step

This complicates method validation and ICH compliance.

iv. Environmental Restrictions on Solvent Use

Conventional solvents like acetonitrile face:

* Cost fluctuations
* Sustainability concerns
* Regulatory pressure to reduce environmental impact

Thus, developing greener yet high-performance chromatographic systems is challenging.

v. Challenges in Real-World Sample Analysis

Anti-malarial formulations used in low-resource regions face unique issues such as:

* Poor storage conditions
* Counterfeit products
* High humidity and temperature variability.

Analytical methods must therefore be extremely robust, fast, and field-friendly.

vi. Need for Harmonized Global Standards

Differences in

* Regional regulatory requirements
* Pharmacopeial guidelines
* Analytical validation expectations

Make standardization of stability-indicating RP-HPLC methods difficult across countries.

8. CONCLUSION

Stability-indicating RP-HPLC methods are vital for ensuring the quality and safety of fixed-dose anti-malarial combinations. Advances in chromatographic materials, green analytical practices, PDA/MS detection, and QbD-driven methodologies have greatly enhanced sensitivity, specificity, and robustness. Despite the chemical complexity of anti-malarial FDCs, modern RP-HPLC techniques effectively resolve active components and their degradation products under varied stress conditions. Future research should focus on greener solvents, automation, hyphenated chromatographic techniques, and real-time stability testing to meet evolving regulatory demands and global malaria eradication needs.

Future research will emphasize greener, more sensitive, QbD-driven and MS-integrated analytical platforms. However, challenges related to the complexity of anti-malarial FDCs, lack of impurity standards, and environmental constraints must be addressed to achieve global standardization and robustness.

9. REFERENCES

1. Snyder, L.R., Kirkland, J.J., Dolan, J.W. Introduction to Modern Liquid Chromatography. 3rd ed. Wiley, 2011.
2. Dong, M.W. Modern HPLC for Practicing Scientists. Wiley-Interscience; 2006.
3. Kazakevich, Y., Lobrutto, R. HPLC for Pharmaceutical Scientists. Wiley; 2007.
4. Bakshi, M., Singh, B. Pharmaceutical Stability Testing to Support Global Markets. Elsevier; 2018.
5. Ahuja, S., Alsante, K.M. Handbook of Isolation and Characterization of Impurities in Pharmaceuticals. Elsevier, 2003.
6. Ahuja, S., Dong, M. Handbook of Pharmaceutical Analysis by HPLC. Academic Press; 2005.
7. Blessy, M., Patel, R.D., Prajapati, P.N., Agrawal, Y.K. Development of stability-indicating methods using forced degradation studies: A review. Journal of Pharmaceutical Analysis, 2014; 4(3): 159–165.
8. Ritu, G., Singh, R. Stability-indicating RP-HPLC methods in pharmaceutical quality control: A comprehensive review. Critical Reviews in Analytical Chemistry, 2018; 48(1): 15–29.
9. Kaushal, J., Singh, P. Forced degradation studies and stability-indicating methods: A review. Journal

of Applied Pharmaceutical Science, 2016; 6(3): 159–167.
10. Phani Kumar, V., Reddy, K.R. Analytical methods for antimalarial drugs: A detailed review. Journal of Pharmaceutical Sciences and Research, 2017; 9(6): 805–814.
11. Nair, A., Jacob, S. HPLC methods for antimalarial drugs: An updated review. International Journal of Pharmaceutical Sciences Review and Research. 2015; 32(1): 110–118.
12. Jain, R., Shah, M., Trivedi, P. Stability-indicating RP-HPLC method for simultaneous estimation of Artemether and Lumefantrine in tablets. Journal of Chromatographic Science. 2013; 51(6): 471–477.
13. Mehta, F., Bhatt, D.A. Development and validation of an RP-HPLC method for Artesunate and Amodiaquine in combined dosage form. Indian Journal of Pharmaceutical Sciences, 2015; 77(1): 68–72.
14. Raju, S.A., Rao, J.V., Reddy, K.S. Stability-indicating HPLC method for simultaneous estimation of dihydroartemisinin and Piperaquine. Acta Poloniae Pharmaceutica, 2014; 71(2): 331–338.
15. Patel, G.F., Patel, K.B. RP-HPLC method for determination of Sulfadoxine and Pyrimethamine in FDC tablets. Journal of Liquid Chromatography & Related Technologies, 2016; 39(9): 443–450.
16. Kalyankar, T.M., Kasture, A.V. Stability-indicating chromatographic method for determination of Artesunate and Mefloquine. Biomedical Chromatography, 2017; 31(3): e3823.
17. Teshale, C., Alemayehu, M. Stability studies of Artemether–Lumefantrine: RP-HPLC analytical characterization. Malaria Journal, 2018; 17(1): 463.
18. ICH Q1A (R2). Stability Testing of New Drug Substances and Products. International Council for Harmonisation, 2003.
19. ICH Q2 (R2). Validation of Analytical Procedures – Method Validation. ICH; 2022.
20. WHO. WHO Prequalification: Guidelines for Stability Testing of Pharmaceutical Products. World Health Organization; 2018.
21. United States Pharmacopeia (USP). General Chapter <621> Chromatography. USP-NF; 2022.
22. European Pharmacopoeia. Monographs on Antimalarial Drugs and ACTs. EDQM; 2021.
23. Peraman, R., Bhadraya, K., Reddy, Y.P. Analytical Quality by Design (AQbD) in pharmaceutical development: A comprehensive review. Saudi Pharmaceutical Journal, 2015; 23(6): 634–643.
24. Ribeiro, F.A., de Souza, F.R., Collins, C.H. Green liquid chromatography in pharmaceutical analysis: Advances and future challenges. Journal of Chromatography A., 2020; 1620: 460980.